Home » Stocks » XLRN

Acceleron Pharma, Inc. (XLRN)

Stock Price: $116.99 USD 3.24 (2.85%)
Updated November 27, 12:32 PM EST - Market open

Stock Price Chart

Key Info

Market Cap 7.05B
Revenue (ttm) 106.00M
Net Income (ttm) -132.21M
Shares Out 60.25M
EPS (ttm) -2.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $116.99
Previous Close $113.75
Change ($) 3.24
Change (%) 2.85%
Day's Open 114.47
Day's Range 113.79 - 117.75
Day's Volume 192,173
52-Week Range 46.00 - 124.01

More Stats

Market Cap 7.05B
Enterprise Value 6.19B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 60.25M
Float 52.51M
EPS (basic) -2.39
EPS (diluted) -2.40
FCF / Share -1.89
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.60M
Short Ratio 12.15
Short % of Float 6.85%
Beta 0.52
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 66.50
PB Ratio 7.64
Revenue 106.00M
Operating Income -135.29M
Net Income -132.21M
Free Cash Flow -112.87M
Net Cash 860.51M
Net Cash / Share 14.28
Gross Margin -75.44%
Operating Margin -127.64%
Profit Margin -124.70%
FCF Margin -106.49%
ROA -11.53%
ROE -19.44%
ROIC -63.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (13)

Buy 11
Overweight 0
Hold 1
Underweight 0
Sell 1

Analyst Consensus: Buy

Price Target

(12.63% upside)
Current: $116.99
Target: 131.77
*Average 12-month price target from 13 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth428.86%3.78%-51.46%53.46%23.68%-74.43%275.18%-81.15%-
Gross Profit73.9913.9913.4827.7718.1014.6357.2315.2579.41
Operating Income-136-124-110-66.11-60.88-55.466.95-28.8938.56
Net Income-125-119-108-57.01-63.89-51.26-21.90-32.5870.42
Shares Outstanding52.4545.9040.4237.4333.3031.529.412.402.33
Earnings Per Share-2.38-2.59-2.68-1.52-1.92-1.63-4.15-24.840.78
Operating Cash Flow-93.80-94.71-76.54-44.55-44.21-53.22-19.65-38.889.06
Capital Expenditures-3.29-2.59-4.40-3.38-0.96-0.51-0.31-0.44-0.03
Free Cash Flow-97.09-97.30-80.94-47.93-45.17-53.73-19.96-39.339.03
Cash & Equivalents43129127814110617711440.5265.95
Total Debt26.38-----16.8720.196.00
Net Cash / Debt40529127814110617797.2120.3359.95
Book Value44929236522610915657.81-291-233
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Acceleron Pharma, Inc.
Country United States
Employees 237
CEO Habib J. Dable

Stock Information

Ticker Symbol XLRN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: XLRN
IPO Date September 19, 2013


Acceleron Pharma, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.